DiaMedica Therapeutics Inc.

NasdaqCM:DMAC Stok Raporu

Piyasa değeri: US$197.6m

DiaMedica Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

DiaMedica Therapeutics CEO'su Rick Pauls, Jan2010 tarihinde atandı, in görev süresi 14.83 yıldır. in toplam yıllık tazminatı $ 1.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 46.2% maaş ve 53.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 316.90K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 5.5 yıldır.

Anahtar bilgiler

Rick Pauls

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi46.2%
CEO görev süresi14.8yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi2.2yrs
Yönetim Kurulu ortalama görev süresi5.5yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Nov 23
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

May 16
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 12
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold

Jul 06

We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

Jun 16
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate

We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

Jan 04
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely

DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.

Nov 05

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Jun 13

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

May 01
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

Feb 13
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?

We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

Jan 09
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn

DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

CEO Tazminat Analizi

Rick Pauls'un ücretlendirmesi DiaMedica Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$22m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$562k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$1mUS$523k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$477k

-US$14m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$878kUS$455k

-US$12m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$2mUS$420k

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$734kUS$315k

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$502kUS$280k

-US$4m

Tazminat ve Piyasa: Rick 'ın toplam tazminatı ($USD 1.22M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.46M ).

Tazminat ve Kazançlar: Rick şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Rick Pauls (53 yo)

14.8yrs

Görev süresi

US$1,215,161

Tazminat

Mr. Dietrich John Pauls, also known as Rick, MBA has been Chief Executive Officer and President of DiaMedica Therapeutics Inc. since January 2010 and has been its Director since April 2005. Mr. Pauls was a...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dietrich Pauls
President14.8yrsUS$1.22m0.16%
$ 316.9k
Scott Kellen
CFO & Corporate Secretary6.6yrsUS$632.22k0.076%
$ 149.2k
Ambarish Shah
Chief Technology Officer1.2yrsVeri yokVeri yok
Dominic Cundari
Chief Commercial Officer2.8yrsVeri yok0.0066%
$ 12.9k
David Wambeke
Chief Business Officer1.6yrsVeri yok1.23%
$ 2.4m
Lorianne Masuoka
Chief Medical Officerless than a yearVeri yokVeri yok

2.2yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: DMAC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dietrich Pauls
President19.6yrsUS$1.22m0.16%
$ 316.9k
James Parsons
Independent Director9.1yrsUS$97.18k0.0053%
$ 10.4k
R. Giuffre
Independent Director14.3yrsUS$90.93k0.76%
$ 1.5m
George L. Bakris
Member of Kidney Scientific Advisory Board5.5yrsVeri yokVeri yok
Richard Pilnik
Independent Chairman15.5yrsUS$133.98k0.33%
$ 653.5k
Glenn Chertow
Member of Kidney Scientific Advisory Board5.5yrsVeri yokVeri yok
Rajiv Agarwal
Member of Kidney Scientific Advisory Board5.5yrsVeri yokVeri yok
Philip Bath
Member of Stroke Advisory Board1.8yrsVeri yokVeri yok
Scott Kasner
Member of Stroke Clinical Advisory Boardno dataVeri yokVeri yok
Charles Herzog
Member of Kidney Scientific Advisory Boardno dataVeri yokVeri yok
John Volpi
Member of Stroke Clinical Advisory Boardno dataVeri yokVeri yok
Aldo Peixoto
Member of Kidney Scientific Advisory Board5.5yrsVeri yokVeri yok

5.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DMAC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).